Phase 3 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to sign a consent form and agree to follow all study requirements for the full length of the study
- You are 60 years of age or older at the time of joining
- You have had a normal eye scan (OCT) and visual field test within the last 6 months
- You are able to swallow and take oral (by mouth) medication
- You have been diagnosed with lupus (SLE) for at least 7 years, confirmed by standard medical criteria
- Your lupus is currently stable and well-controlled, with very low or no disease activity, and you are not taking immune-suppressing medications
- You have not had a moderate or severe lupus flare-up in the past year
- You have been taking hydroxychloroquine (HCQ) at a dose of at least 200mg per day for 7 years or more
Who may not be able to join:
- Your lupus is not considered stable or well-controlled at the time of screening
- You have signs of eye damage to the retina that may be linked to hydroxychloroquine use
- Your lupus disease activity score shows any active disease
- You are currently taking more than 5mg per day of prednisone or an equivalent steroid
- You are currently taking any immune-suppressing or biological medications (such as methotrexate, azathioprine, rituximab, or similar drugs)
- Your doctor has concerns about ongoing lupus activity that may not show up in standard tests
- Your hydroxychloroquine blood level is very low (below 100 ng/ml), which may suggest the medication is not being taken regularly
- You are unwilling or unable to follow the study procedures for any reason
- You have a diagnosis of dementia, cognitive impairment, or any condition that may affect your ability to make decisions (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Izmirly, NYU Langone Health
Phone: (212) 263-0372
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants who Develop Moderate or Severe Flare based on the Revised SELENA SLEDAI Flare Index (rSFI)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.